Anti-VGFR2/ KDR/ CD309 monoclonal antibody

Anti-VGFR2/ KDR/ CD309 antibody for FACS & in-vivo assay

Target products collectionGo to KDR/KDR products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T80975-Ab-1/ GM-Tg-hg-T80975-Ab-2Anti-Human KDR monoclonal antibodyHuman
GM-Tg-rg-T80975-Ab-1/ GM-Tg-rg-T80975-Ab-2Anti-Rat KDR monoclonal antibodyRat
GM-Tg-mg-T80975-Ab-1/ GM-Tg-mg-T80975-Ab-2Anti-Mouse KDR monoclonal antibodyMouse
GM-Tg-cynog-T80975-Ab-1/ GM-Tg-cynog-T80975-Ab-2Anti-Cynomolgus/ Rhesus macaque KDR monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T80975-Ab-1/ GM-Tg-felg-T80975-Ab-2Anti-Feline KDR monoclonal antibodyFeline
GM-Tg-cang-T80975-Ab-1/ GM-Tg-cang-T80975-Ab-2Anti-Canine KDR monoclonal antibodyCanine
GM-Tg-bovg-T80975-Ab-1/ GM-Tg-bovg-T80975-Ab-2Anti-Bovine KDR monoclonal antibodyBovine
GM-Tg-equg-T80975-Ab-1/ GM-Tg-equg-T80975-Ab-2Anti-Equine KDR monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T80975-Ab-1/ GM-Tg-hg-T80975-Ab-2; GM-Tg-rg-T80975-Ab-1/ GM-Tg-rg-T80975-Ab-2;
GM-Tg-mg-T80975-Ab-1/ GM-Tg-mg-T80975-Ab-2; GM-Tg-cynog-T80975-Ab-1/ GM-Tg-cynog-T80975-Ab-2;
GM-Tg-felg-T80975-Ab-1/ GM-Tg-felg-T80975-Ab-2; GM-Tg-cang-T80975-Ab-1/ GM-Tg-cang-T80975-Ab-2;
GM-Tg-bovg-T80975-Ab-1/ GM-Tg-bovg-T80975-Ab-2; GM-Tg-equg-T80975-Ab-1/ GM-Tg-equg-T80975-Ab-2
Products NameAnti-KDR monoclonal antibody
Formatmab
Target NameKDR
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KDR benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-632Pre-Made Vulinacimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody
    BiosimilarGMP-Bios-ab-396Pre-Made Olinvacimab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
    BiosimilarGMP-Bios-ab-468Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
    BiosimilarGMP-Bios-ab-687Pre-Made Pulocimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody
    BiosimilarGMP-Bios-ab-014Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
    BiosimilarGMP-Bios-ab-550Pre-Made Tanibirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species VGFR2/ KDR/ CD309 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T80975-Ag-1Kinase insert domain receptor (KDR) protein


    Target information

    Target IDGM-T80975
    Target NameKDR
    Gene ID3791,16542,25589,698293,482154,101090260,407170,100033959
    Gene Symbol and Synonyms6130401C07,CD309,FLK,Flk-1,FLK1,KDR,Krd-1,Ly73,orv,sVEGFR-2,VEGFR,VEGFR-2,VEGFR2
    Uniprot AccessionP35968,O08775
    Uniprot Entry NameVGFR2_HUMAN,VGFR2_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000128052
    Target ClassificationCheckpoint-Immuno Oncology, Kinase, Tumor-associated antigen (TAA)

    The target: KDR, gene name: KDR, also named as CD309, FLK1, VEGFR, VEGFR2. Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.